Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry.
A method has been developed for the simultaneous quantification of metformin (I) and glipizide (II) in human plasma. It is based on high-performance liquid chromatography with electrospray ionization tandem mass (LC-ESI-MS/MS) spectrometric detection in positive ionization mode. Phenformin (III) and gliclazide (IV) were used as internal standards for I and II, respectively. The MS/MS detection was performed in multiple reaction monitoring (MRM) mode. The precursor-product ion combinations of m/z 130 --> 71, 446 --> 321, 206 --> 60 and 324 --> 127 were used to quantify I, II, III and IV, respectively. This method was validated in the concentration ranges of 0.02-4 microg/mL for I and 0.004-0.8 microg/mL for II. It was utilized to support a clinical pharmacokinetic study after single dose oral administration of a combination of I and II.
Ding
Cun-Gang
CG
Shanghai Institute of Pharmaceutical Industry, 1111 Zhongshan North One Road, Shanghai 200437, People's Republic of China.
Zhou
Zhen
Z
Ge
Qing-Hua
QH
Zhi
Xiao-Jin
XJ
Ma
Li-Li
LL
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005913:Glipizide / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008687:Metformin / Q000097:blood* / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods*
D008687:Metformin; D005913:Glipizide